Higher percentage of CD34 + CD38− cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Plesa, Adriana; Elhamri, Mohamed; Clapisson, Gilles; Mattei, Eve; Gazzo, Sophie; Hequet, Olivier; Tigaud, Isabelle; Michallet, Mauricette; Dumontet, Charles; Thomas, Xavier
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 3(2015:Mar.)
• Page Start: 622
• Page End: 629
• Publication Date: 2015-03
• Subjects: Acute myeloid leukemia -- prognosis -- stem cell harvest -- autologous transplant -- leukemia stem cell; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.927453
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Relapse in acute myeloid leukemia (AML) after chemotherapy reflects the persistence of resistant leukemia stem cells (LSCs). These cells have been described in the CD34 + CD38− cell fraction. Leukapheresis products were harvested in 123 patients in morphological complete remission and analyzed by multiparameter flow cytometry. The CD34 + CD38− cell population showed a prognostic impact on survival. Median event-free survival (EFS) was 8.2 months (3-year EFS: 29%) for those with a higher percentage of CD34 + CD38− versus 91.9 months (3-year EFS: 62%) for those with a lower percentage for the entire cohort. These differences were confirmed in patients undergoing autologous stem cell transplant, with median EFS of 7.3 months versus 91.1 months (3-year EFS: 31% vs. 70%). Higher proportions of CD34 + CD38− cells were associated with adverse cytogenetics and with earlier relapses. Higher percentages of CD34 + CD38− cells in apheresis products reflect inadequate in vivo purging and reliably distinguish samples enriched in LSCs from those involving mainly normal cells.